Guangzhou Patronus Biotech Co., Ltd.
Stories
-
Guangzhou Patronus registers Phase III trial of LYB005 RSV vaccine in older adults
The Guangzhou Patronus Biotech Co., Ltd. study plans to enroll an estimate of 25000 participants aged 60 years and older, with a planned start date of November 2026 and a planned primary completion date of September 2027. The trial is randomized, observer-blind, and placebo-controlled.